NCT04867915 Study on the Diagnosis and Management of CLL in Italy by GIMEMA
| NCT ID | NCT04867915 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Condition | Chronic Lymphocytic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,500 participants |
| Start Date | 2021-10-13 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,500 participants in total. It began in 2021-10-13 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
retrospective and prospective multicenter observational clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL. retrospective cohort: all cases with a diagnosis between January 1st 2010 and August 31th 2021. prospective cohort: all patients with a diagnosis between September 1st 2021 and September 1st 2025.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years at diagnosis 2. One of the following diagnoses that meet the international diagnostic criteria (iwCLL2018 and WHO2017) 1. Chronic lymphocytic leukemia (CLL) 2. Small lymphocytic lymphoma (SLL) 3. CLL-like monoclonal B-cell lymphocytosis (MBL) 3. Retrospective cohort: CLL/SLL/MBL diagnosis between January 1st 2010 and August 31th 2021. 4. Prospective cohort: CLL/SLL/MBL diagnosis between September 1st 2021 and September 1st, 2025. 5. Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable) Exclusion Criteria: * \- -
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04867915 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04867915 currently recruiting?
Yes, NCT04867915 is actively recruiting participants. Contact the research team at p.fazi@gimema.it for enrollment information.
Where is the NCT04867915 trial being conducted?
This trial is being conducted at Alessandria, Italy, Brescia, Italy, Brindisi, Italy, Candiolo, Italy and 11 additional locations.
Who is sponsoring the NCT04867915 clinical trial?
NCT04867915 is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. The trial plans to enroll 12,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.